The initiation of coverage by Wolfe Research with a Peer Perform rating suggests that the analyst sees CRISPR Therapeutics performing in line with its peers, without significant short-term upside or downside. This neutral stance may not significantly impact the stock price in the short term, but it brings attention to CRSP from investors following Wolfe Research's analyses.